MedPharm Expands US Center of Excellence

Article

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletterPharmaceutical Technology\'s In the Lab eNewsletter-02-06-2019
Volume 14
Issue 2

The company will invest $4 million to increase topical and transdermal formulation development and performance testing services at its Durham, NC, facility.

On Jan. 11, 2019, MedPharm, a contract provider of topical and transdermal product design and formulation development services, announced the $4-million expansion of its center of excellence in Durham, NC.

The expansion creates additional laboratory space for development programs and topical dosage formulation development services and performance testing on topical and transdermal pharmaceutical products. The company reports that the investment in facility expansion and equipment will more than triple the existing footprint of the facility to 25,000 ft2.

Additionally, the company has increased its liquid chromatography–mass spectrometry (LC/MS) capacity and the automation of sample handling. As part of the investment, MedPharm has installed the latest Waters LC-MS/MS for bio-analysis. This new model is equipped with the latest ultra-performance liquid chromatography for rapid separation and method development and offers mass spectrometry detection at picogram levels, according to MedPharm.

“This expansion aligns with MedPharm’s strategy to keep increasing the sophistication and relevance of our proprietary ex-vivo human skin models and further increase our responsiveness to clients in formulation development, especially in ocular delivery,” said Eugene Ciolfi, MedPharm’s president and CEO, in a company press release. “The expansion complements the recent expansion we have completed in our facility at our headquarters in Guildford, UK, and reflects the positive demand for our services globally.”

Source: MedPharm

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content